The autism spectrum disorders stem cell resource at children’s hospital of orange county: Implications for disease modeling and drug discovery

David J. Brick, Hubert E. Nethercott, Samantha Montesano, Maria G. Banuelos, Alexander E. Stover, Soleil Sun Schutte, Diane K. O’dowd, Randi J Hagerman, Michele Ono, David R Hessl, Flora Tassone, Philip H. Schwartz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The autism spectrum disorders (ASDs) comprise a set of neurodevelopmental disorders that are, at best, poorly understood but are the fastest growing developmental disorders in the United States. Because animal models of polygenic disorders such as the ASDs are difficult to validate, the derivation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming offers an alternative strategy for identifying the cellular mechanisms contributing to ASDs and the development of new treatment options. Access to statistically relevant numbers of ASD patient cell lines, however, is still a limiting factor for the field.Wedescribe a new resource with more than 200 cell lines (fibroblasts, iPSC clones, neural stem cells, glia) from unaffected volunteers and patients with a wide range of clinical ASD diagnoses, including fragile X syndrome.Wehave shown that both normal and ASD-specific iPSCs can be differentiated toward a neural stem cell phenotype and terminally differentiated into actionpotential firing neurons and glia. The ability to evaluate and compare data from a number of different cell lines will facilitate greater insight into the cause or causes and biology of the ASDs and will be extremely useful for uncovering new therapeutic and diagnostic targets. Some drug treatments have already shown promise in reversing the neurobiological abnormalities in iPSC-based models of ASDassociated diseases. The ASD Stem Cell Resource at the Children’s Hospital of Orange County will continue expanding its collection and make all lines available on request with the goal of advancing the use of ASD patient cells as disease models by the scientific community.

Original languageEnglish (US)
Pages (from-to)1275-1287
Number of pages13
JournalStem cells translational medicine
Volume3
Issue number11
DOIs
StatePublished - 2014

Fingerprint

Drug Discovery
Stem Cells
Induced Pluripotent Stem Cells
Neural Stem Cells
Cell Line
Neuroglia
Autism Spectrum Disorder
Fragile X Syndrome
Aptitude
Volunteers
Therapeutics
Animal Models
Clone Cells
Fibroblasts
Phenotype
Neurons
Pharmaceutical Preparations

Keywords

  • Autism spectrum disorder
  • Differentiation
  • Disease modeling
  • Induced pluripotent stem cells
  • Neural stem cell
  • Neuron

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Brick, D. J., Nethercott, H. E., Montesano, S., Banuelos, M. G., Stover, A. E., Schutte, S. S., ... Schwartz, P. H. (2014). The autism spectrum disorders stem cell resource at children’s hospital of orange county: Implications for disease modeling and drug discovery. Stem cells translational medicine, 3(11), 1275-1287. https://doi.org/10.5966/sctm.2014-0073

The autism spectrum disorders stem cell resource at children’s hospital of orange county : Implications for disease modeling and drug discovery. / Brick, David J.; Nethercott, Hubert E.; Montesano, Samantha; Banuelos, Maria G.; Stover, Alexander E.; Schutte, Soleil Sun; O’dowd, Diane K.; Hagerman, Randi J; Ono, Michele; Hessl, David R; Tassone, Flora; Schwartz, Philip H.

In: Stem cells translational medicine, Vol. 3, No. 11, 2014, p. 1275-1287.

Research output: Contribution to journalArticle

Brick, David J. ; Nethercott, Hubert E. ; Montesano, Samantha ; Banuelos, Maria G. ; Stover, Alexander E. ; Schutte, Soleil Sun ; O’dowd, Diane K. ; Hagerman, Randi J ; Ono, Michele ; Hessl, David R ; Tassone, Flora ; Schwartz, Philip H. / The autism spectrum disorders stem cell resource at children’s hospital of orange county : Implications for disease modeling and drug discovery. In: Stem cells translational medicine. 2014 ; Vol. 3, No. 11. pp. 1275-1287.
@article{df749995176c4dda8367e3ecdde65cbb,
title = "The autism spectrum disorders stem cell resource at children’s hospital of orange county: Implications for disease modeling and drug discovery",
abstract = "The autism spectrum disorders (ASDs) comprise a set of neurodevelopmental disorders that are, at best, poorly understood but are the fastest growing developmental disorders in the United States. Because animal models of polygenic disorders such as the ASDs are difficult to validate, the derivation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming offers an alternative strategy for identifying the cellular mechanisms contributing to ASDs and the development of new treatment options. Access to statistically relevant numbers of ASD patient cell lines, however, is still a limiting factor for the field.Wedescribe a new resource with more than 200 cell lines (fibroblasts, iPSC clones, neural stem cells, glia) from unaffected volunteers and patients with a wide range of clinical ASD diagnoses, including fragile X syndrome.Wehave shown that both normal and ASD-specific iPSCs can be differentiated toward a neural stem cell phenotype and terminally differentiated into actionpotential firing neurons and glia. The ability to evaluate and compare data from a number of different cell lines will facilitate greater insight into the cause or causes and biology of the ASDs and will be extremely useful for uncovering new therapeutic and diagnostic targets. Some drug treatments have already shown promise in reversing the neurobiological abnormalities in iPSC-based models of ASDassociated diseases. The ASD Stem Cell Resource at the Children’s Hospital of Orange County will continue expanding its collection and make all lines available on request with the goal of advancing the use of ASD patient cells as disease models by the scientific community.",
keywords = "Autism spectrum disorder, Differentiation, Disease modeling, Induced pluripotent stem cells, Neural stem cell, Neuron",
author = "Brick, {David J.} and Nethercott, {Hubert E.} and Samantha Montesano and Banuelos, {Maria G.} and Stover, {Alexander E.} and Schutte, {Soleil Sun} and O’dowd, {Diane K.} and Hagerman, {Randi J} and Michele Ono and Hessl, {David R} and Flora Tassone and Schwartz, {Philip H.}",
year = "2014",
doi = "10.5966/sctm.2014-0073",
language = "English (US)",
volume = "3",
pages = "1275--1287",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "11",

}

TY - JOUR

T1 - The autism spectrum disorders stem cell resource at children’s hospital of orange county

T2 - Implications for disease modeling and drug discovery

AU - Brick, David J.

AU - Nethercott, Hubert E.

AU - Montesano, Samantha

AU - Banuelos, Maria G.

AU - Stover, Alexander E.

AU - Schutte, Soleil Sun

AU - O’dowd, Diane K.

AU - Hagerman, Randi J

AU - Ono, Michele

AU - Hessl, David R

AU - Tassone, Flora

AU - Schwartz, Philip H.

PY - 2014

Y1 - 2014

N2 - The autism spectrum disorders (ASDs) comprise a set of neurodevelopmental disorders that are, at best, poorly understood but are the fastest growing developmental disorders in the United States. Because animal models of polygenic disorders such as the ASDs are difficult to validate, the derivation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming offers an alternative strategy for identifying the cellular mechanisms contributing to ASDs and the development of new treatment options. Access to statistically relevant numbers of ASD patient cell lines, however, is still a limiting factor for the field.Wedescribe a new resource with more than 200 cell lines (fibroblasts, iPSC clones, neural stem cells, glia) from unaffected volunteers and patients with a wide range of clinical ASD diagnoses, including fragile X syndrome.Wehave shown that both normal and ASD-specific iPSCs can be differentiated toward a neural stem cell phenotype and terminally differentiated into actionpotential firing neurons and glia. The ability to evaluate and compare data from a number of different cell lines will facilitate greater insight into the cause or causes and biology of the ASDs and will be extremely useful for uncovering new therapeutic and diagnostic targets. Some drug treatments have already shown promise in reversing the neurobiological abnormalities in iPSC-based models of ASDassociated diseases. The ASD Stem Cell Resource at the Children’s Hospital of Orange County will continue expanding its collection and make all lines available on request with the goal of advancing the use of ASD patient cells as disease models by the scientific community.

AB - The autism spectrum disorders (ASDs) comprise a set of neurodevelopmental disorders that are, at best, poorly understood but are the fastest growing developmental disorders in the United States. Because animal models of polygenic disorders such as the ASDs are difficult to validate, the derivation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming offers an alternative strategy for identifying the cellular mechanisms contributing to ASDs and the development of new treatment options. Access to statistically relevant numbers of ASD patient cell lines, however, is still a limiting factor for the field.Wedescribe a new resource with more than 200 cell lines (fibroblasts, iPSC clones, neural stem cells, glia) from unaffected volunteers and patients with a wide range of clinical ASD diagnoses, including fragile X syndrome.Wehave shown that both normal and ASD-specific iPSCs can be differentiated toward a neural stem cell phenotype and terminally differentiated into actionpotential firing neurons and glia. The ability to evaluate and compare data from a number of different cell lines will facilitate greater insight into the cause or causes and biology of the ASDs and will be extremely useful for uncovering new therapeutic and diagnostic targets. Some drug treatments have already shown promise in reversing the neurobiological abnormalities in iPSC-based models of ASDassociated diseases. The ASD Stem Cell Resource at the Children’s Hospital of Orange County will continue expanding its collection and make all lines available on request with the goal of advancing the use of ASD patient cells as disease models by the scientific community.

KW - Autism spectrum disorder

KW - Differentiation

KW - Disease modeling

KW - Induced pluripotent stem cells

KW - Neural stem cell

KW - Neuron

UR - http://www.scopus.com/inward/record.url?scp=84908374745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908374745&partnerID=8YFLogxK

U2 - 10.5966/sctm.2014-0073

DO - 10.5966/sctm.2014-0073

M3 - Article

C2 - 25273538

AN - SCOPUS:84908374745

VL - 3

SP - 1275

EP - 1287

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 11

ER -